Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies

1

Selpercatinib showed the most significant progression-free survival benefit compared to cabozantinib and vandetanib in advanced medullary thyroid cancer.
2

The network meta-analysis included five randomized controlled trials with a total of 1,076 patients evaluating RET-targeted therapies for advanced MTC.
3

Selpercatinib ranked first for objective response rate, significantly outperforming other multi-kinase inhibitors in the analysis.
4

Selpercatinib demonstrated a favorable safety profile, with no significant difference in ≥Grade 3 adverse events compared to placebo.
5

Anlotinib exhibited the highest toxicity among the agents studied, while selpercatinib avoided common off-target toxicities associated with multi-kinase inhibitors.

1